Dentsply Sirona upgraded to Outperform at Baird » 08:1704/0804/08/20
As reported previously,…
As reported previously, Baird analyst Jeffrey Johnson upgraded Dentsply Sirona to Outperform from Neutral with a price target of $49, down from $57. The analyst believes Primescan/Primemill can still drive a 2021 recovery. He also said he hears larges DSO's are inching closer to direct supply agreements with the three largest manufacturers, a positive for Dentsply Sirona.
Dentsply Sirona upgraded to Outperform from Neutral at Baird » 05:4004/0804/08/20
Baird analyst Jeffrey…
Story temporarily locked.
Henry Schein upgraded to Buy from Neutral at Goldman Sachs » 07:3504/0704/07/20
Goldman Sachs analyst…
Goldman Sachs analyst Nathan Rich upgraded Henry Schein to Buy from Neutral with a price target of $59, down from $64. Henry Schein faces lower earnings risk than dental peers from the COVID outbreak and its business may be quicker to recover, said Rich, who noted that during the last recession its earnings were more stable and the stock performed better than peers. He cites its relatively higher exposure to consumables and benefits to its Medical segment from the distribution of COVID tests.
Dentsply Sirona downgraded to Neutral from Buy at Goldman Sachs » 07:3004/0704/07/20
Goldman Sachs analyst…
Goldman Sachs analyst Nathan Rich downgraded Dentsply Sirona to Neutral from Buy with a price target of $40, down from $58, as he expects reduced capital investment to persist given that he sees dental practices being under meaningful financial pressure from revenue lost during the COVID crisis. Dentsply Sirona is more leveraged to capital equipment than peers, said Rich, who foresees lower demand for high-ticket products like Primescan and Primemill.
XpresSpa pursues COVID-19 screening, testing at U.S. airports » 09:2204/0304/03/20
XSPA, DGX, AYTU, HSIC
XpresSpa Group (XSPA)…
XpresSpa Group (XSPA) provided an update on recent discussions with local airport authorities and healthcare partners so that it may begin providing screening and testing for novel coronavirus at U.S. airports. COVID-19 screening and testing would be conducted by converting select existing spa locations for this purpose on an interim basis and over time, potentially adding separate, standalone airport locations as testing sites. XpresSpa's U.S. airport real estate portfolio consists of 46 locations across 23 airports that are ready to be reactivated and redeployed in short order, subject to the approval of local airport authorities. The Company's global spas are temporarily closed due to recent local government mandates categorizing its traditional services as "non-essential services". Since March 19, 2020, XpresSpa has been advancing discussions with healthcare partners to develop a model for COVID-19 screening and testing in U.S. airports as a much-needed public service. The Company has also recently filed paperwork in the State of Delaware to form a new business unit to administer such screening and testing capabilities, XpresTest, Inc., as a wholly-owned subsidiary of XpresSpa Group, Inc. While nothing definitive has yet been finalized, XpresSpa is currently in discussions with three major airports, JFK International Airport, Hartsfield-Jackson Atlanta International Airport and Chicago O'Hare International Airport to pilot COVID-19 screening and testing for airline employees, contractors and workers, concessionaires and their employees, TSA agents, and U.S. Customs and Border Protection agents. The Company is also in the process of recruiting a medical director who would work alongside healthcare officials to help design safe and compliant protocols and train employees. The Company recently announced its partnership with Relevant Healthcare. Relevant Healthcare is currently offering clinical diagnostic testing for COVID-19 through its contracts with Laboratory Corporation of America and Quest Diagnostics (DGX) to support full COVID-19 RT-PCR testing. In addition, the Company is also in active discussions with Aytu Biosciences (AYTU), a marketer of a COVID-19 IgG/IgM Rapid Test, and Henry Schein Medical (HSIC), the developer of the Standard Q COVID-19 test, to deploy their respective rapid antibody blood testing solutions. XpresSpa would also partner with Healthalytica. Healthalytica would be charged with processing claims, insurance payments and distributing test result data to the appropriate local, state, and national authorities.
Align Technology completes acquisition of exocad » 08:2004/0204/02/20
Align Technology announced that it has completed the acquisition of privately-held exocad Global Holdings GmbH, a leader in the dental CAD/CAM software market that offers fully integrated workflows to dental labs and dental practices via a broad customer base of partners and resellers in over 150 countries. The acquisition of exocad broadens Align's digital platform reach by adding technology that addresses restorative needs in an end-to-end digital platform workflow to facilitate ortho-restorative and comprehensive dentistry. The acquisition brings exocad's expertise in restorative dentistry, implantology, guided surgery, and smile design to the Align technology portfolio. It extends Align's Invisalign and iTero digital solutions, paving the way for new, seamless cross-disciplinary dentistry in the lab and at chairside. exocad also broadens Align's platform reach in the digital dentistry with close to 200 partners and more than 35,000 licenses installed worldwide. exocad will continue to operate as it exists today, enabling it to support a broad ecosystem of partners and end-users and continue to deliver hardware-independent software solutions. exocad co-founders Tillmann Steinbrecher and Maik Gerth, along with their team, will remain with the Company and report into John Morici, Align Technology, senior vice president and CFO. Align plans to maintain all exocad products and services.
Dentsply Sirona upgraded to Outperform from Peer Perform at Wolfe Research » 06:5004/0204/02/20
Wolfe Research analyst…
Wolfe Research analyst Steve Beuchaw upgraded Dentsply Sirona to Outperform from Peer Perform with a $66 price target.
Henry Schein upgraded to Outperform from Peer Perform at Wolfe Research » 06:5004/0204/02/20
Wolfe Research analyst…
Wolfe Research analyst Steve Beuchaw upgraded Henry Schein to Outperform from Peer Perform with a $68 price target.
|Over a week ago|
Henry Schein named exclusive distributor of second COVID-19 rapid test kit » 07:1304/0104/01/20
Henry Schein (HSIC)…
Henry Schein (HSIC) announced that it will serve as the exclusive distributor in the United States of a second point-of-care rapid test kit that can detect antibodies associated with COVID-19 in as few as 15 minutes. Working with Becton Dickinson (BDX) and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, Henry Schein will make the test kits available to health care professionals as part of the company's broad offering of point-of-care rapid tests. The BioMedomics test analyzes blood, serum, or plasma samples for the presence of Immunoglobulin M, or IgM, and Immunoglobulin G, or IgG, antibodies associated with the coronavirus. The test is completed in four steps. First, blood is collected through normal blood collection devices, and then a few drops are transferred to the test cartridge, followed by two to three drops of a buffer. The results can be read in 15 minutes. The agreement with BD and BioMedomics builds on Henry Schein's announcement last week of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, which is also administered at the point of care and delivers results within 15 minutes from a pinprick with no instrumentation required. The company is also a participant in the White House's COVID-19 Supply Chain Task Force, and has worked with the Strategic National Stockpile to deliver PPE to COVID-19 testing sites. As part of that effort, the company is working with the Federal Emergency Management Agency to source and deliver critical supplies quickly.
Becton Dickinson, BioMedomics launch test to detect exposure to COVID-19 » 16:0303/3103/31/20
Becton Dickinson (BDX)…
Becton Dickinson (BDX) and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes. The new test, developed and manufactured by BioMedomics, will be available through BD and distributed exclusively by Henry Schein, Inc. to health care providers throughout the United States. The test does not require special equipment and may be used in a laboratory or at the point of care. The test detects antibodies in the blood that are produced by the body in response to coronavirus infection. These antibodies are typically present in the middle to later stages of COVID-19 infection, but may remain present after exposure, which helps clinicians determine who has been exposed to the coronavirus, even if a person didn't exhibit any symptoms of the COVID-19 disease. Data on past exposure is important for researchers to more accurately understand the likely true occurrence of SARS-CoV-2 infection across a population. This information will be helpful in informing future strategies for combatting COVID-19. The test is completed in four, simple steps. First, blood is collected through normal blood collection devices such as the BD Microtainer Contact-Activated Lancet. A few drops of blood are then transferred to the test cartridge, followed by two to three drops of a buffer. The results can be read in 15 minutes, similar to how over-the-counter pregnancy tests show multiple lines for positive results and a single line for negative results. The test has not been reviewed by the FDA but is permitted for distribution and use under the public health emergency guidance issued by FDA on March 16, 2020, and BD expects to begin shipping tests in April. BD will have capacity to supply more than one million tests over the coming months, with the ability to scale up based on market demand and is working with medical products distribution company Henry Schein (HSIC) to make these tests available to medical care facilities throughout the United States. Health care providers can order the test and all collection devices needed to perform the test by contacting their BD or Henry Schein representatives.